Efficacy and Safety of Finasteride Therapy for Androgenetic Alopecia

Mella, José M.; Perret, María Clara; Manzotti, M; Catalano, H; Guyatt, Gordon

doi:10.1001/archdermatol.2010.256

Cited by 194 publications

(151 citation statements)

References 31 publications

Supporting

Mentioning

123

Contrasting

Unclassified

Order By: Relevance

“…Finasteride was initially FDA approved for use in benign prostate hyperplasia (BPH), but seeing the hair growth as a side effect, it was adopted to treat AGA in 1997. The underlying principle for its use in AGA is the reduction of DHT production in order to limit its action on scalp hair follicles [12][13][14].…”

Section: Introductionmentioning

confidence: 99%

Efficacy of a Nutritional Supplement, Standardized in Fatty Acids and Phytosterols, on Hair Loss and Hair Health in both Women and Men

Zanzottera¹,

Nobile²,

Bizzaro³

et al. 2017

J Cosmo Trichol

View full text Add to dashboard Cite

Introduction: Hair health concern is one of the most distressing conditions for a significant number of men and women of all ages. The unique current pharmacologic therapeutic options approved by Food and Drug administration (FDA) are finasteride and topical minoxidil; however, these treatments may have side effects and may work on just one cause of hair loss, without giving an exhaustive and complete results.

show abstract

Section: Introductionmentioning

confidence: 99%

Efficacy of a Nutritional Supplement, Standardized in Fatty Acids and Phytosterols, on Hair Loss and Hair Health in both Women and Men

Zanzottera¹,

Nobile²,

Bizzaro³

et al. 2017

J Cosmo Trichol

View full text Add to dashboard Cite

show abstract

“…However, the effi cacy was not comparable to minoxidil 5% solution which is widely used topical formulation for the treatment of alopecia DISCUSSION FNS is drug of choice for the treatment of androgenetic alopecia since it was approved by US Food and Drug Administration in 1997. However, the use of the drug has been implicated in problematic side effects such as sexual disturbance and gynecomastia (Mella et al, 2010). Furthermore, the drug is associated with incidence of high-grade prostate cancer (Thompson et al, 2003;Thompson et al, 2008;Lebdai et al, 2010).…”

Section: Resultsmentioning

confidence: 99%

Effect of Charge Carrier Lipid on Skin Penetration, Retention, and Hair Growth of Topically Applied Finasteride-Containing Liposomes

Lee¹,

Kumar²,

Sriraman³

et al. 2011

Biomolecules and Therapeutics

View full text Add to dashboard Cite

The aim of this study was to investigate the effect of charge carrier lipid on the skin penetration, retention, and hair growth of topically applied fi nasteride-containing liposomes. Finasteride-containing liposomes were prepared by traditional thin fi lm hydration method using Phospholipon ® 85 G and cholesterol with or without charge carrier lipid (1,2 dimyristoyl-sn-glycero-3-phosphate or 1,2-dioleoyl-trimethylammonium-propane for anionic and cationic charge, respectively). Freshly prepared fi nasteride-containing liposome suspension was applied on the hairless mouse skin, and skin penetration and retention were measured using KesharyChien diffusion cell. Non-liposomal formulation (ethanol 10% solution containing 0.5 mg/ml of FNS) was also used as a control. The amount of fi nasteride in the diffusion cell and mouse skin was measured by HPLC. The hair growth was evaluated using depilated male C57BL/6N mice. Mean particle size of all fi nasteride-containing liposomes was less than a micron, and polydispersity index revealed size homogeneity. Skin penetration and retention studies showed that signifi cantly less amount of fi nasteride was penetrated when applied as anionic liposome while more amount of the drug was retained. Specifi cally, in liposome prepared with 10% anionic charge carrier lipid, penetration was 12.99 μg/cm 2 while retention was 79.23 μg/cm 2 after 24 h of application. In hair growth study, fi nasteride-containing anionic liposomes showed moderate effi cacy, but the effi cacy was not found when applied as cationic liposomes. In conclusion, topical application of fi nasteride using anionic liposome formulation appears to be useful option for the treatment of androgenetic alopecia to avoid systemic side effects of the drug. Abstract cifi c inhibitor towards type II 5α-reductase, an intracellular enzyme that converts testosterone into 5α-dihydrotestosterone which is believed to cause androgenetic alopecia. There are two distinct isozymes of the enzyme, i.e., type I and type II. In humans, type I 5α-reductase is predominantly expressed in the sebaceous glands of most regions of skin. In contrast, type II 5α-reductase is predominantly found in hair follicles where hair growth begins as well as prostate, seminal vesicles, and epididymis. Therefore, FNS is widely used for the treatment of androgenetic alopecia and benign prostate hyperplasia.Although FNS is effective in the treatment of androgenetic alopecia, oral use of this drug is largely limited due to various side effects such as erectile dysfunction and impotence. Another serious adverse effect includes gynecomastia, develop-

show abstract

“…Mella, et al [88], published a systematic review to assess the efficacy and safety of finasteride therapy for AGA, when compared to placebo. The authors report that moderate-quality evidence of the studied articles showed that daily use of oral finasteride increases hair count and improves patient and investigator assessment of hair appearance.…”

Section: Alpha Reductase Inhibitorsmentioning

confidence: 99%

Androgenetic Alopecia: a Review and Emerging Treatments

Alves¹

2017

CRDOA

View full text Add to dashboard Cite

Androgenetic Alopecia (AGA) is the most common noncicatricial alopecia that leads to the progressive miniaturization of the hair follicle. Scalp terminal hairs are converted into vellus hairs, primarily due to two factors: genetic predisposition and hormonal stimulation.The incidence and prevalence of AGA increases with age. The onset of AGA is gradual, and when this pathology progresses, the anagen phase shortens and the telogen phase remains constant. The shedding area varies from patient to patient and is usually most marked at the vertex in men, while women with AGA generally lose hair diffusely over the crown.Topical minoxidil and oral finasteride (5-alpha-reductase type II inhibitor) are the gold-standard therapies for AGA and are currently the only Food and Drug Administration (FDA)-approved drugs for the treatment of AGA.The currently available treatments for AGA are sometimes perceived as having limited effectiveness; therefore, the identification of new therapies for this pathology is of utmost importance.This article aims to review the pathogenesis, diagnosis of AGA and all the new emerging treatments for this entity in order to prevent its progression and improve the results of this pathology.

show abstract

Efficacy and Safety of Finasteride Therapy for Androgenetic Alopecia

Cited by 194 publications

References 31 publications

Efficacy of a Nutritional Supplement, Standardized in Fatty Acids and Phytosterols, on Hair Loss and Hair Health in both Women and Men

Efficacy of a Nutritional Supplement, Standardized in Fatty Acids and Phytosterols, on Hair Loss and Hair Health in both Women and Men

Effect of Charge Carrier Lipid on Skin Penetration, Retention, and Hair Growth of Topically Applied Finasteride-Containing Liposomes

Androgenetic Alopecia: a Review and Emerging Treatments

Contact Info

Product

Resources

About